UBS raised the firm’s price target on CG Oncology (CGON) to $90 from $60 and keeps a Buy rating on the shares. CG Oncology’s Phase 3 PIVOT-006 trial is evaluating adjuvant cretostimogene post-TURBT in low- and high-grade intermediate-risk NMIBC, a condition affecting about 50K patients with high recurrence rates, the analyst tells investors in a research note. The trial aims to address the limitations of current standard-of-care by providing durable disease control with a favorable safety profile, with topline data expected in 1H26, the firm adds.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Cretostimogene’s PIVOT‑6 Upside: Anticipated Superiority in Recurrence‑Free Survival Supports Buy on CG Oncology
- CG Oncology price target raised to $72 from $65 at BofA
- Buy Rating on CG Oncology Driven by PIVOT-006 Differentiation and 2026 Clinical, Regulatory Catalysts Supporting Favorable Risk–Reward
- CG Oncology: Advancing Creto Toward 2026 BLA with Pivotal PIVOT‑006 Catalyst and Expanding NMIBC Peak Sales Potential
- CG Oncology price target raised to $80 from $75 at H.C. Wainwright